Merck & Co., Inc. (MRK)

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).

As of November 3, 2026, Merck & Co., Inc. (MRK) stock slipped to $146.02, down 1.58% (-$2.34) versus the previous close. On the day, shares have traded between $145.74 and $147.62. That puts MRK in the upper third of its 52-week range of $82.01 to $156.92. Merck & Co., Inc. operates in the pharmaceutical preparations space and carries a market capitalization of roughly $368.89 billion, with about 664.5K shares changing hands.

Latest MRK news

• What Could Derail Bristol Myers Squibb Stock?trefis.com· Nov 3, 9:12 AM ET
• Buy, Sell, or Hold? Tuesday’s Top Upgrades and Downgrades: AON, Bloom Energy, Chevron, Cloudflare, Marvell Technologies, Lumentum Holdings, Merck & Co., Roku, X-Energy, and More247wallst.com· Nov 3, 7:59 AM ET
• Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of ExacerbationsYahoo Finance· Nov 3, 6:45 AM ETCOPDSOC
• How to Invest in the Rise of China’s Biotech: Buy U.S. Drug StocksYahoo Finance· Nov 3, 6:15 AM ET
• Merck to Divest CDMO Business to LonzaYahoo Finance· Nov 3, 1:45 AM ET
• Betting On Drug Sales: Is Viatris Or Lilly The Better Way In?trefis.com· Nov 2, 3:21 PM ET
• BTK Inhibitors Market to Expand During the Forecast Period (2026–2036) as Targeted Treatments Advance Across B-Cell Malignancies and Autoimmune Disorders | DelveInsightYahoo Finance· Nov 2, 1:00 PM ET
• Merck Stocks Decline With Higher Target Leaving a New-Launch Scale TestYahoo Finance· Nov 2, 11:45 AM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want MRK headlines, alerts and AI research in one place? Create a free account →

• $MRK - Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations

  @ripster47· Nov 3, 7:02 AM ET

• Did any investors believe the $MRK or $MRNA CEO about Intismeran? The paper below outlines how it will be another mRNA failure https://www.nature.com/articles/s43018-024-00794-1?error=cookies_not_supported&code=cd0c1e26-4cef-4fc9-8deb-37c2d16e280c

  @taxplanr· Nov 3, 6:47 AM ET· Bearish

• $IBRX and may the exec’s running $MRK rot in hell for doing nothing to improve the bcg supply whe they knew had shortage for 10 yrs while pushing keytruda for everyone except baldness!

  @TearsForFear· Nov 2, 4:28 PM ET

• #Biotechnology #Stocks Break Out To Leadership Position With Growth Mentions: $ABBV $GILD $LLY $MRK $IBB https://talkmarkets.com/article/biotechnology-stocks-break-out-to-leadership-position-with-growth

  @TalkMarkets· Nov 2, 3:16 PM ET

• $INO $MRK $PGEN $SLS Brokerage firms calling Retail Shorts to cover now or they will do a forced liquidation Cover after multiple attempts. Shorts 🔥 22,500,000 trapped. ✌️🙏❤️‍🩹

  @SellasgpsCurativeBAT11· Nov 2, 1:34 PM ET· Bullish

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →